New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:34 EDTINCYIncyte duration of response not an issue, says Jefferies
Jefferies says the shorter than expected duration of response for Incyte's '360 with ipilimumab is not an issue since the progression-free survival number is strong. Jefferies believes last night's data suggests that '360 offers up to three times the clinical benefit expected with ipilimumab alone. It maintains a Buy rating on Incyte shares with an $80 price target.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
05:57 EDTINCYIncyte price target raised to $121 from $80 at Piper Jaffray
Subscribe for More Information
April 20, 2015
08:47 EDTINCYIncyte price target raised to $120 from $93 at SunTrust
Subscribe for More Information
April 17, 2015
07:33 EDTINCYIncyte no longer expects to initiate INCB39110 trial in pancreatic cancer in '15
Incyte Corporation announced that eleven abstracts detailing its emerging development pipeline will be presented at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. These abstracts include characterizations of Incyte’s FGFR, BRD and PIM inhibitors as potential targeted therapies for cancer, as well as data supporting the potential immuno-therapeutic activity of the company’s portfolio of JAK and PI3Kδ inhibitors alone and in combination, including with epacadostat, Incyte’s leading IDO1 inhibitor. The company also provided an updated presentation of its clinical portfolio, which now includes INCB54828, a potent and selective FGFR inhibitor and INCB50465, a PI3Kδ inhibitor, which entered clinical trials in Q1 2015 for solid tumors and B-lymphoid malignancies. INCB54329, a bromodomain inhibitor, is expected to enter clinical trials in Q2 2015 in hematology oncology. Additional first-line pancreatic cancer patients are being recruited into the expansion cohort of JAK1-selective inhibitor INCB39110 in combination with gemcitabine and nab-paclitaxel to continue the dose optimization phase of this proof-of-concept trial. Incyte therefore no longer expects to initiate a pivotal trial of INCB39110 in first-line pancreatic cancer during 2015.
April 14, 2015
07:31 EDTINCYIncyte to establish European headquarters in Geneva, Switzerland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use